Erythromycin is a macrolide antibiotic.
Erythromycin base is administered orally. The manufacturers of erythromycin delayed-release tablets state that these tablets are well absorbed and may be given without regard to meals.124 The manufacturers of erythromycin delayed-release capsules (containing enteric-coated pellets)123 and erythromycin film-coated tablets125 state that optimal absorption generally occurs when these preparations are administered in the fasting state (at least 30 minutes and, preferably, 2 hours before or after meals). Delayed-release tablets containing enteric-coated particles are well absorbed in most patients and may be given without regard to meals, but the manufacturer states that optimal absorption still occurs if such tablets are administered in the fasting state (at least 30 minutes and, preferably, 2 hours before meals).104
The commercially available delayed-release capsules containing enteric-coated pellets of erythromycin (ERYC®) may be swallowed intact or the entire contents of a capsule(s) may be sprinkled on a small amount of applesauce immediately prior to administration; subdividing the contents of a capsule is not recommended. The enteric-coated pellets contained in the capsules should not be chewed or crushed. If the capsule contents are administered by sprinkling on applesauce, the patient should drink some water after swallowing the applesauce to ensure that the pellets are swallowed. If the pellets are accidentally spilled, the dose preparation should be started over with a new capsule.
The usual adult oral dosage of erythromycin is 250 mg every 6 hours,123,124,125 333 mg every 8 hours,104,124,125 or 500 mg every 12 hours.104,123,124,125 In severe infections, dosage may be increased up to 4 g daily; however, a twice-daily dosing schedule is not recommended when dosages exceeding 1 g daily are administered.104,123,124
The usual oral erythromycin dosage in children is 30-50 mg/kg daily given in 2-4 equally divided doses.104,107,123,124,125 For more severe infections, this dosage may be doubled but should not exceed 4 g daily.104,123,124,125 A twice-daily dosing schedule is not recommended when dosages exceeding 1 g daily are administered.104,123,124
If erythromycin is used for the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β-hemolytic streptococci), the drug should be given in the usual dosage for 10 days or longer.102,104,107,124,125
Prophylaxis of Recurrent Rheumatic Fever
For continuous prophylaxis to prevent recurrences in patients with a history of rheumatic heart disease, the usual oral dosage of erythromycin is 250 mg twice daily.102,104,107,123,124,125
When selecting anti-infectives for prophylaxis of recurrent rheumatic fever, the current recommendations published by the American Heart Association (AHA) should be consulted.102
Although penicillin G is the drug of choice for all stages of syphilis,100,101,107 the manufacturers state that 30-40 g of oral erythromycin has been given in divided doses over 10-15 days for the treatment of primary syphilis.104,123,124,125 Erythromycin is no longer included in US Centers for Disease Control and Prevention (CDC) recommendations for the treatment of any form of syphilis in adults or adolescents (including primary, secondary, latent, or tertiary syphilis or neurosyphilis) and is not recommended for the treatment of congenital syphilis or syphilis in older infants and children.101 In addition, erythromycin is no longer recommended by the CDC or American Academy of Pediatrics (AAP) for the treatment of syphilis in pregnant women who are hypersensitive to penicillin since numerous treatment failures (including in the fetus) have been reported with the drug.101,107
For the treatment of early localized or early disseminated Lyme disease associated with erythema migrans (but without neurologic involvement or third-degree AV heart block) in adults who are allergic to or intolerant of penicillins and cephalosporins and in whom tetracyclines are contraindicated, the Infectious Diseases Society of America (IDSA) suggests an oral erythromycin dosage of 500 mg 4 times daily for 14-21 days.103 For the treatment of early localized or early disseminated Lyme disease associated with erythema migrans (but without neurologic involvement or third-degree AV heart block) in children who are allergic to or intolerant of penicillins or cephalosporins and cannot receive a tetracycline (e.g., younger than 8 years of age), the IDSA suggests an oral erythromycin dosage of 12.5 mg/kg (maximum dose: 500 mg) 4 times daily for 14-21 days.103 Some clinicians suggest that if erythromycin is used in the treatment of early Lyme disease, adults should receive 250 mg 4 times daily for 14-21 days and children should receive 30 mg/kg daily in 3 divided doses (or 250 mg 3 times daily) for 14-21 days.111 However, erythromycin may not be as effective as other recommended agents (e.g., oral doxycycline, oral amoxicillin) for the treatment of Lyme disease,107,108,109,110 and patients treated with macrolides should be monitored closely.103 For additional details on the manifestations of Lyme disease and the efficacy of various anti-infective regimens in early or late Lyme disease, see Lyme Disease in Uses: Spirochetal Infections, in the Tetracyclines General Statement 8:12.24.
Gonorrhea and Associated Infections
When an oral erythromycin is indicated for the treatment of coexisting chlamydial infections in conjunction with therapy of uncomplicated or disseminated gonococcal infections, the CDC recommends that adults and adolescents receive 500 mg of erythromycin orally 4 times daily for 7 days.101 Erythromycins generally are indicated for these infections in pregnant women and in other adults when tetracyclines are contraindicated or not tolerated.101 (See Uses: Gonorrhea and Associated Infections, in the Erythromycins General Statement 8:12.12.04.)
The AAP currently recommends that all children beyond the neonatal period being treated for uncomplicated vulvovaginal, urethral, or pharyngeal gonorrhea, epididymitis, proctitis, or disseminated gonococcal infections including meningitis or endocarditis receive presumptive treatment for possible coexisting chlamydial infections.107 If oral erythromycin is used for presumptive treatment of chlamydial infection in children who weigh less than 45 kg, the AAP recommends a dosage of 50 mg/kg daily (maximum 2 g daily) given in 4 divided doses for 7 days.107
Although erythromycin is not included in the current CDC recommendations for the treatment of acute pelvic inflammatory disease (PID) caused by N. gonorrhoeae ,101 some manufacturers recommend a regimen of 500 mg of erythromycin (as the lactobionate) IV every 6 hours for 3 days followed by an oral regimen of 333 mg of erythromycin (as the base or stearate) every 8 hours for 7 days or 500 mg every 12 hours for 7 days for the treatment of these infections.104,124,125 However, some clinicians believe this oral dosage is inadequate and recommend 500 mg every 6 hours for 7-10 days.
When oral erythromycin is used as an alternative to azithromycin or doxycycline for the treatment of nongonococcal urethritis in adults and adolescents, the CDC and others recommend a regimen of 500 mg of erythromycin 4 times daily for 7 days.100,101 Alternatively, a regimen of 666 mg of erythromycin may be given every 8 hours for at least 7 days.104,124
Patients with recurrent and persistent urethritis who were not compliant with the full course of erythromycin therapy or who were reexposed to untreated sexual partner(s) should receive a second course of oral erythromycin.101 If the patient has recurrent and persistent urethritis, was compliant with the regimen, and reexposure can be excluded, the CDC recommends a regimen of 500 mg of oral erythromycin 4 times daily for 7 days given in conjunction with a single 2-g dose of oral metronidazole.101
For the treatment of uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis in nonpregnant adults and adolescents when azithromycin or doxycycline cannot be used, the CDC and others recommend oral erythromycin in a dosage of 500 mg 4 times daily for 7 days.100,101,104,107,123,124,125 Alternatively, a dosage of 666 mg every 8 hours for 7 days can be used.104,124 The dosage of oral erythromycin recommended by the CDC for the treatment of these infections in children weighing 45 kg or less is 50 mg/kg daily given in 4 divided doses for 14 days.101
For the treatment of chlamydial urogenital infections during pregnancy, the recommended dosage of oral erythromycin is 500 mg 4 times daily or 666 mg every 8 hours for at least 7 days.100,101,104,123,124,125 Women who cannot tolerate this regimen may receive a dosage of 500 mg every 12 hours, 333 mg every 8 hours, or 250 mg 4 times daily for at least 14 days.104,124
For the treatment of pneumonia caused by C. trachomatis in infants, the recommended dosage of oral erythromycin is 50 mg/kg daily given in 4 divided doses for 14 days;100,101,107 follow-up is recommended and a second course of therapy may be necessary.101,107
For the treatment of ophthalmia neonatorum caused by C. trachomatis , the recommended dosage of oral erythromycin is 50 mg/kg daily given in 4 divided doses for 14 days;100,101,107 follow-up is recommended and a second course of therapy may be necessary.101,107
If erythromycin is used as an alternative to doxycycline for the treatment of genital, inguinal, or anorectal infections caused by a lymphogranuloma venereum serotype of C. trachomatis , the CDC and others recommend that adults and adolescents receive an oral dosage of 500 mg 4 times daily for 21 days.100,101,107
For the treatment of chancroid (genital ulcers caused by Haemophilus ducreyi ), the CDC and others recommend that adults receive an oral erythromycin dosage of 500 mg 3-4 times daily for 7 days.100,101
The CDC recommends that patients with chancroid be examined 3-7 days after initiation of anti-infective therapy.101 If the regimen was effective, symptomatic improvement in the ulcers is evident within 3 days and objective improvement is evident within 7 days.101 The time required for complete healing is related to the size of the ulcer; large ulcers may require more than 2 weeks to heal.101 Healing of ulcers may be slower in uncircumcised men who have ulcers under the foreskin.101 Resolution of fluctuant lymphadenopathy is slower than that of ulcers, and needle aspiration or incision and drainage may be necessary even during otherwise effective anti-infective therapy.101 While needle aspiration of buboes is a simpler procedure, incision and drainage of buboes may be preferred.101 If clinical improvement is not evident within 3-7 days, consideration should be given to the possibility that the diagnosis was incorrect, there is coinfection with another sexually transmitted disease, the patient was noncompliant with the regimen, the strain of H. ducreyi is resistant to the anti-infective agent used, or the patient is HIV seropositive.101 (See Uses: Chancroid in the Erythromycins General Statement 8:12.12.04.)
Granuloma Inguinale (Donovanosis)
When oral erythromycin is used as an alternative to co-trimoxazole or doxycycline for the treatment of granuloma inguinale (Donovanosis) caused by Calymmatobacterium granulomatis (e.g., in pregnant or lactating women), the CDC recommends a dosage of 500 mg orally 4 times daily for at least 3 weeks.101 If lesions do not respond within the first few days of therapy, some experts recommend that a parenteral aminoglycoside (e.g., 1 mg/kg of gentamicin IV every 8 hours) be added to the regimen.101 Addition of an aminoglycoside should be strongly considered when treating donovanosis in pregnant or lactating women or in patients with human immunodeficiency virus (HIV) infection.101 Despite effective anti-infective therapy, donovanosis may relapse 6-18 months later.101
Although erythromycin is not considered a drug of choice for the treatment of intestinal amebiasis caused by Entamoeba histolytica ,107 the manufacturers state that adults may receive 250 mg of erythromycin every 6 hours,104,123,125 333 mg every 8 hours,104 or 500 mg every 12 hours104,125 for 10-14 days and that children may be given 30-50 mg/kg daily in divided doses for 10-14 days.104,123,124,125
When used as an adjunct to diphtheria antitoxin for the treatment of diphtheria, the usual dosage of erythromycin is 40-50 mg/kg daily (maximum 2 g daily) for 14 days.107,126 Patients usually are no longer contagious 48 hours after initiation of anti-infective therapy.126 Eradication of the organism should be confirmed by 2 consecutive negative cultures following completion of therapy.107,126
For prevention of diphtheria in household or intimate contacts of patients with respiratory or cutaneous diphtheria, the CDC and US Public Health Service Advisory Committee on Immunization Practices (ACIP) recommend that children receive erythromycin in a dosage of 40 mg/kg daily and that adults receive 1 g daily for 7-10 days.106,126 The American Academy of Pediatrics (AAP) recommends that these contacts receive an erythromycin dosage of 40-50 mg/kg daily (maximum 2 g daily) for 7 days.107
Household or intimate contacts of patients with diphtheria should receive anti-infective prophylaxis regardless of their immunization status and should be closely monitored for symptoms of diphtheria for 7 days.106,107,126 In addition, contacts who are inadequately immunized against diphtheria (i.e., have previously received fewer than 3 doses of diphtheria toxoid) or whose immunization status is unknown should receive an immediate dose of an age-appropriate diphtheria toxoid preparation and the primary series should be completed according to the recommended schedule.107,126 Contacts who are fully immunized should receive an immediate booster dose of an age-appropriate diphtheria toxoid preparation if it has been 5 years or longer since their last booster dose.107,126
When erythromycin is used to eliminate the diphtheria carrier state in identified carriers of toxigenic Corynebacterium diphtheriae , the ACIP and AAP recommend that adults and children receive 7-10 days of the drug in the dosages specified above for prevention of diphtheria.106,107 Follow-up cultures should be obtained at least 2 weeks after completion of therapy; if cultures are positive, an additional 10-day course of oral erythromycin should be given and additional follow-up cultures obtained.106,107
Although the optimum dosage and duration of erythromycin for the treatment of pertussis or prevention in susceptible contacts have not been established, a dosage of 1 g daily in adults and 40-50 mg/kg daily (maximum 2 g daily) in children given in divided doses for 14 days usually is recommended.106,107 While a shorter duration of erythromycin therapy (e.g., 7 or 10 days) may be effective in some patients, 107,112 prophylaxis failures and bacteriologic relapse of pertussis have been reported with erythromycin regimens shorter than 14 days.112,113,114,115,116,117,118 Therefore, the CDC,126 ACIP,106 AAP,107 and some clinicians113,114,115,116,117,118 recommend that a 14-day course of erythromycin therapy be used for treatment or prevention of pertussis.
Although data from controlled studies are lacking, the CDC recommends that all household and other close contacts of individuals with pertussis receive a 14-day regimen of prophylaxis (regardless of age and vaccination status) since this may prevent or minimize transmission of the disease.126 In addition, all close contacts younger than 7 years of age who are not fully immunized against pertussis should receive the remaining required doses of a preparation containing pertussis vaccine (using minimal intervals between doses) and those who are fully immunized but have not received a vaccine dose within the last 3 years should receive a booster dose of a pertussis vaccine preparation.126
Although the optimum dosage and duration of erythromycin for the treatment of Legionnaires' disease have not been established, dosages of 1-4 g daily in divided doses have been given alone or in combination with rifampin.104,107,119,122,123,124,125 A parenteral regimen usually is necessary for the initial treatment of severe Legionnaires' disease and the addition of rifampin is recommended during the first 3-5 days of therapy in severely ill and/or immunocompromised patients; after a response is obtained, rifampin can be discontinued and therapy changed to oral erythromycin.107,119,122 The duration of therapy in patients with Legionnaires's disease usually is 10-21 days;107,119,122 some clinicians recommend 14 days of therapy for patients with mild disease and 21 days for those who are immunocompromised or have severe disease.107
Preoperative Intestinal Antisepsis
For preoperative intestinal antisepsis in patients undergoing colorectal surgery, oral erythromycin is usually given in conjunction with oral neomycin sulfate as an adjunct to mechanical cleansing of the large intestine. It is generally recommended that if surgery is scheduled for 8 a.m., 1 g of erythromycin and 1 g of neomycin sulfate should be administered at 1 p.m., 2 p.m., and 11 p.m. on the day preceding surgery.105,124
Erythromycin occurs as a white or slightly yellow, odorless or practically odorless, bitter, crystalline powder. The drug has a solubility of approximately 1 mg/mL in water and is soluble in alcohol at 25°C.
Erythromycin delayed-release capsules (containing enteric-coated pellets),123 delayed-release tablets (containing enteric-coated particles),104 delayed-release (enteric coated) tablets,124 and film-coated tablets125 should be stored at a temperature not exceeding 30°C.104 The delayed-release capsules should be protected from moisture and excessive heat.123
Additional Information
For further information on chemistry, mechanism of action, spectrum, resistance, pharmacokinetics, uses, cautions, drug interactions, laboratory test interferences, and dosage and administration of erythromycin, see the Erythromycins General Statement 8:12.12.04.The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer's labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Oral | Capsules, delayed-release (containing enteric-coated pellets) | 250 mg* | ERYC® | Warner Chilcott |
Erythromycin Delayed-Release Capsules | ||||
Tablets, delayed-release (containing enteric-coated particles) | 333 mg | PCE® Dispertab® | Abbott | |
500 mg | PCE® Dispertab® | Abbott | ||
Tablets, delayed-release (enteric-coated) | 250 mg | Ery-Tab® | Abbott | |
333 mg | Ery-Tab® | Abbott | ||
500 mg | Ery-Tab® | Abbott | ||
Tablets, film-coated | 250 mg | Erythromycin Base Filmtab | ||
500 mg | Erythromycin Base Filmtab |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Only references cited for selected revisions after 1984 are available electronically.
100. Anon. Drugs for sexually transmitted infections. Med Lett Treat Guid . 2004; 2:67-74.
101. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep . 2002; 51(No. RR-6):1-78. [Fulltext MMWR]
102. Dajani A, Taubert K, Ferrieri P et al and the American Heart Association Committee on Rheumatic Fever et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics . 1995; 96:758-64. [PubMed 7567345]
103. Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice guidelines for treatment of lyme disease. Clin Infect Dis . 2000; 31(Suppl 1):S1-14. [PubMed 10982743]
104. Abbott Laboratories. PCE® Dispertab® tablets (erythromycin particles in tablets) prescribing information (dated 2000 Feb). In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:498-500.
105. Anon. Antimicrobial prophylaxis in surgery. Med Lett Drug Ther . 2001; 43:92-7.
106. Centers for Disease Control Immunization Practices Advisory Committee (ACIP). Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. MMWR Morb Mortal Wkly Rep . 1991; 40(No. RR-10):1-28. [PubMed 1898620]
107. Committee on Infectious Diseases, American Academy of Pediatrics. 2000 Redbook: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:164-6,203-6,208-12,230-4,254-62,364-5,374-9,435-48,526-36.
108. Nocton JJ, Steere AC. Lyme disease. Adv Intern Med . 1995; 40:69-117. [PubMed 7747659]
109. Nadelman RB, Wormser GP. Erythema migrans and early Lyme disease. Am J Med . 1995; 98(4A):15-23S.
110. Anon. Treatment of Lyme Disease. Med Lett Drugs Ther . 2000; 42:37-9. [PubMed 10825919]
111. Steere AC. Lyme disease. N Engl J Med . 2001; 345:115-25. [PubMed 11450660]
112. Halperin SA, Bortolussi R, Langley JM et al. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics . 1997; 100:65-71. [PubMed 9200361]
113. Bass JW. Erythromycin for pertussis: probable reasons for past failures. Lancet . 1985; 2:147. [PubMed 2862331]
114. Bass JW. Erythromycin for treatment and prevention of pertussis. Pediatr Infect Dis . 1986; 5:154-7. [PubMed 2868449]
115. Bergquist SO, Bernander S, Doahnsjo H et al. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J . 1987; 6:458-61. [PubMed 2885802]
116. Steketee RW, Wassilak SGF, Adkins WN et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis . 1988; 157:434-40. [PubMed 3257783]
117. Halsey NA, Welling MA, Lehman RM. Nosocomial pertussis: a failure of erythromycin treatment and prophylaxis. Am J Dis Child . 1980; 134:421-2.
118. Bass JW. Use of erythromycin in pertussis outbreaks. Pediatrics . 1983; 72:748-9. [PubMed 6356008]
119. Edelstein PH. Legionnaires' disease. Clin Infect Dis . 1993; 16:741-9. [PubMed 8329504]
120. Petersen EA. Prevention of bacterial endocarditis. Arch Intern Med . 1990; 150:2447-8. [PubMed 2244761]
121. American Society of Health-System Pharmacists, Inc. Commission on Therapeutics. ASHP therapeutic guidelines on nonsurgical antimicrobial prophylaxis. Clin Pharm . 1990; 9:423-5. [PubMed 2194737]
122. Stout JE, Yu VL. Legionellosis. N Engl J Med . 1997; 337:682-7. [PubMed 9278466]
123. Abbott Laboratories. Erythromycin delayed-release capsules prescribing information (dated 1991 Sep). In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:455-7.
124. Abbott Laboratories. ERY-TAB (erythromycin delayed-release tablets, enteric-coated) prescribing information (dated 2001 Feb). In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:448-50.
125. Abbott Laboratories. Erythromycin Base Filmtab® (erythromycin tablets) prescribing information (dated 2000 Oct). In: Physicians' desk reference. 56th ed. Montvale, NJ: Medical Economics Company Inc; 2002:454-5.
126. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 7th ed. Public Health Foundation; 2002 Jan:39-48,58-70.